Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
|
|
12.
|
|
|
13.
|
|
|
14.
|
|
|
15.
|
|
|
16.
|
|
|
17.
|
The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro. [electronic resource] by
- Pillai, S
- Duvvuru, S
- Bhatnagar, P
- Foster, W
- Farmen, M
- Shankar, S
- Harris, C
- Bastyr, E
- Hoogwerf, B
- Haupt, A
Producer: 20190111
In:
The pharmacogenomics journal vol. 18
Availability: No items available.
|
|
18.
|
|
|
19.
|
Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. [electronic resource] by
- Bergenstal, R M
- Lunt, H
- Franek, E
- Travert, F
- Mou, J
- Qu, Y
- Antalis, C J
- Hartman, M L
- Rosilio, M
- Jacober, S J
- Bastyr, E J
Producer: 20171031
In:
Diabetes, obesity & metabolism vol. 18
Availability: No items available.
|
|
20.
|
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes. [electronic resource] by
- Cusi, K
- Sanyal, A J
- Zhang, S
- Hoogwerf, B J
- Chang, A M
- Jacober, S J
- Bue-Valleskey, J M
- Higdon, A N
- Bastyr, E J
- Haupt, A
- Hartman, M L
Producer: 20171031
In:
Diabetes, obesity & metabolism vol. 18 Suppl 2
Availability: No items available.
|